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ABSTRACT
Fragile X syndrome, the most frequent form of
inherited mental retardation, is due to the absence
of expression of the Fragile X Mental Retardation
Protein (FMRP), an RNA binding protein with high
specificity for G-quartet RNA structure. FMRP is
involved in several steps of mRNA metabolism:
nucleocytoplasmic trafficking, translational control
and transport along dendrites in neurons. Fragile X
Related Protein 1 (FXR1P), a homologue and inter-
actor of FMRP, has been postulated to have a
function similar to FMRP, leading to the hypothesis
that it can compensate for the absence of FMRP in
Fragile X patients. Here we analyze the ability of
three isoforms of FXR1P, expressed in different
tissues, to bind G-quartet RNA structure specific-
ally. Only the longest FXR1P isoform was found
to be able to bind specifically the G-quartet RNA,
albeit with a lower affinity as compared to FMRP,
whereas the other two isoforms negatively regulate
the affinity of FMRP for G-quartet RNA. This result is
important to decipher the molecular basis of fragile
X syndrome, through the understanding of FMRP
action in the context of its multimolecular complex
in different tissues. In addition, we show that the
action of FXR1P is synergistic rather than compen-
satory for FMRP function.
INTRODUCTION
Fragile X related genes are members of a small gene family
whose founding member is the Fragile X Mental Retardation
1 gene (FMR1). Inactivation of FMR1 causes Fragile X syn-
drome, the most common cause of inherited mental retarda-
tion (1,2). The other members of this family, FXR1 and
FXR2, are autosomal and have not been associated so far
with any human disease (2–4). Animal models have been
generated for Fmr1 deﬁciency, recapitulating the phenotype
of Fragile X syndrome (5,6). Fxr2 null mice are viable and
show some behavioral phenotypes, such as hyperactivity,
similar to those observed in Fmr1 knockout mice (7). Fxr1
null mice die shortly after birth most likely because of
heart and/or respiratory failure due to alterations in muscle
development (8). In Xenopus, complete or partial inactivation
of xFxr1 expression has dramatic muscle-speciﬁc effects (9).
In vertebrates, members of the FXR protein family are
structurally very similar and share a high degree of sequence
homology in clustered regions corresponding to functional
domains (2–4). Like FMRP, FXR1P contains several RNA
binding domains: two KH domains and one RGG box. It
also contains a nuclear localization signal (NLS), a nuclear
export signal (NES) and a protein–protein interaction domain
(2,10). They also share the same gene structure, derived from
their common ancestor in Drosophila melanogaster (11).
FXR proteins are able to bind RNA (3,4), but binding speci-
ﬁcity has been studied in detail only for FMRP. Indeed, even
if a few hundreds of different RNAs have been proposed to be
putative targets of FMRP, only two structures are speciﬁcally
bound by this protein, the G-quartet and the kissing complex
(12–14) and one sequence, a poly(U) stretch (15). FXR1P has
been reported to bind AU rich element (ARE) and, through
the interaction with this element, to regulate the expression of
the proinﬂammatory cytokine tumor necrosis factor (TNFa)
in macrophages (16). In the cytoplasm the three FXR proteins
are associated with polyribosomes (17), while they share
only two interacting proteins, CYFIP2 and MSP58, with
FMRP (2,18,19). The FXR1 primary transcript is alternatively
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see also www.ncbi.nlm.nih.gov/IEB/Research/Acembly/. Of
notice, some of these isoforms are differentially expressed
in various tissues (21). Up to date, the ability of full-length
FXR1P and FXR2P to bind a G-quartet RNA structure in a
speciﬁc manner has not been reported. We analyzed here
the RNA binding properties of the three most abundantly
expressed FXR1P isoforms and show that they have different
afﬁnities for the G-quartet RNA structure. Since all protein
members of the FXR family are able to heterodimerize with
FMRP, they are believed to act together (4). In the present
study we determined that, when complexed to FMRP, FXR1P
isoforms can modulate its afﬁnity for G-quartet RNA and also
the dynamics of this complex. Our data demonstrate that
FXR1P has a synergistic molecular function with FMRP
rather than a redundant role.
MATERIALS AND METHODS
Purification of recombinant proteins
Glutathione S-transferase (GST)-FMRP produced in the
baculovirus system was puriﬁed as described previously
(22). pET21a/FMRP (ISO1) vector was described previously
(23). To construct pGex-4T-1/FMRP, ISO1 cDNA was
excised from pTL1/FMRP ISO1 and subcloned into the
EcoRI/NotI sites of pGex-4T-1 (Amersham). To construct
pET21a/FXR1P, Isoe, Isod and Isoa isoforms were ampliﬁed
by PCR using the primers (Eurogentec): EcoRI forward-50-
GGCGAATTCATGGCGGACGTGACGGTG-30; XhoI reverse-
50-GCCCTCGAGTTATGAAACACCATTCAGGAC -30, the
PCR consisted of 1 cycle at 94 C for 4 min, 30 cycles of
three steps each, 94 C for 30 s followed by 60 C for 30 s
and 68 C for 2 min using the Pfx polymerase (Invitrogen).
PCR fragments were puriﬁed, digested and cloned into the
EcoRI/XhoI sites of pET21a (Novagen). The sequences of the
cDNAs corresponding to the different FXR1P isoforms were
veriﬁed by sequencing. The proteins were produced in bacteria
and puriﬁed following the manufacturer’s protocol. GST-
MSP58 was produced and puriﬁed as described previously (19).
GST-pull down
GST-pull down assays were performed as described previ-
ously (22). Brieﬂy, an increasing amount of recombinant
His-FXR1P (1, 2 or 4 mM) was mixed with 4 mM of GST-
FMRP. Pull down assays were carried out in the following
buffer: [50 mM Tris–HCl (pH 7.4) at 4 C, 1 mM MgCl2,
1 mM EDTA, 150 mM KCl, 1 mM DTT], as described (22).
After washing with the same buffer, the proteins bound to the
beads and their interactors were eluted using 30 mM glu-
tathione and separated by electrophoresis on 8% SDS–
polyacrylamide gels. FMRP was visualized by immunoblot
using the 1C3 monoclonal antibody (24), FXR1P was
revealed by the 3FX monoclonal antibody (21). The proteins
were also visualized on gel by Coomassie staining.
RNA binding assays
The different RNA fragments used in this study, N19
[RNA sequence derived from FMR1 cDNA and containing
a G-quartet forming structure (13)] and N8 [RNA sequence
not containing G-quartet structures and corresponding to the
30-untranslated region (30-UTR) of PP2Ac (25)], were cloned
in pTL1 plasmid. For ﬁlter binding assay, pTL1 plasmids
linearized with PstI were in vitro transcripbed with T7
RNA polymerase (Promega) (13). The RNAs were puriﬁed
using the NucAway Spin columns (Ambion). RNAs were
then ethanol precipitated and resuspended in a appropriate
buffer. For binding experiments, N19 was labeled co-
transcriptionally by incorporation of [a-
32P]ATP. Labeled
RNAs were puriﬁed on a 1% low-melting agarose gel
(Ambion). Labeled RNAs (80 000 c.p.m., 5 fmol) were rena-
tured for 10 min at 40 Ci n4ml of binding buffer [50 mM
Tris–HCl (pH 7.4) at 4 C, 1 mM MgCl2, 1 mM EDTA,
150 mM KCl, 1 mM DTT] in the presence of 8 U RNasin
(Invitrogen), 0, 1 mgo fEscherichia coli total tRNA and
0.01% BSA. An increasing amount of protein was then
added to the RNA. RNA–protein complexes were formed
for 10 min on ice. After incubation, binding solutions were
passed through MF-membrane ﬁlters (0.45 HA, Millipore)
and washed with 2 ml binding buffer. Filters were air dried
and the amount of radioactivity was measured by Cerenkov
counting. Data were plotted as percentage of total RNA
bound versus the protein concentration. Competition experi-
ments to determine the relative binding strength of the differ-
ent proteins to G-quartet RNA were carried out using labeled
N19 RNA incubated with 1 pmol of protein in the presence of
increasing concentrations of unlabeled competitors. FMRP
was used as an internal positive control. For association
rate determination, 5 fmol of labeled N19 were incubated
with 1 pmol of the appropriate protein in the binding buffer
between 10 and 300 min on ice. For dissociation rate deter-
mination, 5 fmol of labeled N19 were incubated with 1
pmol of the appropriate protein in the binding buffer for 10
min on ice, 10
 6 M of competitor RNA (N19 or N8) were
then added to the mixture and incubated between 10 and
300 min. Each binding curve is the result of at least three
independent experiments performed with three replicates for
each binding point. All data obtained for the different experi-
ments of RNA binding, calculating the standard deviation for
each binding point, are shown in Supplementary Data. All the
values and curves were analyzed using the PRISM Graphpad
version 4 Software.
RESULTS
Our ﬁrst aim was to assess whether FXR1P is able to bind
G-quartet RNA structure, which is considered to be a frequent
structure recognized by FMRP and present in many of
its mRNA targets (12,13,26). Due to extensive alternative
splicing of FXR1 mRNA, at least seven isoforms of FXR1P
are differentially expressed in various tissues (20). We
decided to study the RNA binding properties of three
FXR1P isoforms: Isod and Isoa (Figure 1), the two isoforms
most highly expressed in brain (3), and Isoe (Figure 1) that is
a FXR1P isoform highly expressed during myogenesis and in
adult cardiac and skeletal muscle (21). The FXR1P-Isod and
Isoa isoforms both lack exon 12 and 15 and only differ in
their C-terminus due to the choice of a different splicing
acceptor site in the mRNA of the FXR1P-Isoa isoform, result-
ing in a frameshift that induces an early stop codon
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that the only differences between FXR1P-Isod and Isoe iso-
forms are the insertion of 28 amino acid encoded by exon
12 and the presence of 27 amino acid encoded by exon 15
(20,21) (Figure 1A). This 27 amino acid stretch is strongly
recognized as a putative RNA binding motif by two different
predictive programs available online [http://bindr.gdcb.
iastate.edu/RNABindR/main.aspx (27) and http://129.130.
115.77/cgi-bin/bindn.pl (28)], whereas the sequence of exon
12 does not apparently display such properties. The presence
or absence of exon 15 raises then the possibility that the 3 iso-
forms share different RNA binding abilities.
As the tissue distribution of FXR1P isoforms had not been
investigated completely, we performed RT–PCR on various
RNA samples extracted from cell lines and tissues. FXR1P
containing exon 15 RNA was detected at very low level in
brain, and in particular in the cerebellum, cortex and hip-
pocampus, as well as in the neuroblastoma cell line NG108,
together with FXR1P isoforms lacking exon 15 (data not
shown).
To investigate the G-quartet binding properties of the three
FXR1P isoforms, we generated in a bacterial system recom-
binant FXR1P isoforms: Isoe, Isod and Isoa (Figure 1A)
(3,21), FMRP ISO1 (29) and as a control MSP58, a recently
described G-quartet binding protein (19), tagged with His or
GST (Figure 1B).
In a ﬁlter binding assay, recombinant FMRP protein pro-
duced in bacteria displays the same afﬁnity for RNA contain-
ing a G-quartet structure as recombinant FMRP produced in
an insect cell system (data not shown), conﬁrming that the
system of production does not change FMRP afﬁnity for
G-quartet RNA, in agreement with studies by Darnell and
colleagues (30). Also it has been shown that FMRP acts as
a nucleic acids chaperone in low-salt binding conditions
(31) and is also able to bind RNA non-speciﬁcally, raising
the possibility of introduction of a bias in the assesment of
its binding afﬁnities, as already suggested (13,32). Consider-
ing the high level of homology that exists between the FXR
proteins (4), we reasoned that FXR1P could also display the
same properties of aspeciﬁc binding to RNA. As a result, to
assess the RNA binding properties of FXR1P isoforms, we
used the rigorous and sensitive RNA competition assays,
which alleviate the contribution of aspeciﬁc binding (13,25).
Using the previously described ﬁlter binding assay (30), we
observed that FXR1P-Isod and Isoa isoforms do not bind spe-
ciﬁcally G-quartet RNA structure since the amount of bound
G-quartet radiolabeled probe is not competed by either the
unlabeled G-quartet RNA [N19, corresponding to the portion
of the FMR1 transcript containing the G-quartet structure
(13)] or another RNA not containing G-quartet structures
and not binding FMRP [N8, corresponding to the 30-UTR
of the PP2Ac transcript (25)] (Figure 2B). Indeed, at the equi-
librium state, the dissociation constant (Kd) is around 5 mM
for FXR1P-Isod isoform and 0.8 mM for FXR1P-Isoa.
Conversely, FXR1P-Isoe binds G-quartet RNA but with a
lower afﬁnity compared to FMRP or MSP58 (Figure 2A).
As little as 1 nM of competitor RNA is able to displace
50% of FMRP from G-quartet labeled probe, whereas  10
nM are necessary for FXR1P-Isoe (Figure 2A). When we
used as competitor the N8 probe, that does not bind FMRP
(25), no binding was observed for all proteins analyzed
here (Figure 2B). To conﬁrm that FXR1P-Isoe interaction
with G-quartet RNA is speciﬁc for the structure, we per-
formed the binding assay either in the presence of K
+ or in
the presence of Na
+. Indeed, FXR1P-Isoe, like FMRP and
MSP58 (13,19) is unable to bind G-quartet containing
FMR1 RNA in the presence of Na
+, a cation destabilizing
the G-quartet structure (Figure 2C). This ﬁnding suggests that
the effect observed is not due to the recognition of a speciﬁc
RNA sequence, but to the G-quartet structure localized in
Figure 1. The FXR1P isoforms. (A) Schematic representation of the C-terminal region of the three FXR1P isoforms analyzed: Isoe 84 kDa, Isod 78 kDa, Isoa
70 kDa. In the upper part of the figure the alternatively spliced sequences are indicated. A (+) under each amino acid indicates the predicted ability of the
sequence to bind RNA accordingly to the algorithm described by Terribilini and coworkers (28). (B) Production of recombinant proteins. Equal amounts of
Hist-FMRP, His-FXR1P-Isoe, Isod, Isoa and GST-MSP58 were loaded on a 10% SDS–PAGE gel and revealed by Coomassie blue staining.
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analysis by competing the binding of
32P-labeled N19 probe
with the G-quartet forming RNA structures obtained from
the 50-UTR of PP2Ac (that contains four G-quartet forming
structures) (25) and obtained the same results (data not
shown) that are described in Figure 2A using N19 RNA
competition.
Since FXR1P isoforms display different G-quartet binding
speciﬁcity, we asked whether they would affect differently
FMRP binding afﬁnity to G-quartet. First, we veriﬁed the
Figure 2. RNA binding properties of FMRP and FXR1P isoforms. (A) Filter binding assay using FMRP, FXR1P-Isoe, Isod, Isoa and MSP58. The RNA probe
used is
32P-labeled N19 RNA, and competition was performed using the same unlabeled RNA. (B) The same experiment was repeated using as competitor the N8
RNA sequence, not containaing any G-quartet forming structure. (C) Filter binding assay was repeated with an increasing amount of FMRP and Isoe in the
presence of Na
+ or K
+.( D) GST-pull down was performed as described in Materials and Methods. On the right part of (D), proteins used in GST-pull down assay
were revealed by immunoblot. FMRP was detected by monoclonal 1C3 antibody, FXR1P by the monoclonal 3FX antibody. Lane 1: 4 mM GST-FMRP
complexed with 1 mM His-FXR1P, Lane 2: 4 mM GST-FMRP complexed with 2 mM His-FXR1P, Lane 3: 4 mM GST-FMRP complexed with 4 mM His-FXR1P.
On the left part of (D), proteins used in GST-pull down experiment were revealed by Coomassie stained gel. (E) Competition assay to determine the Kd at the
equilibrium state binding FMRP, the heterodimers FMRP/Isoe, FMRP/Isod, FMRP/Isoa and the complex FMRP/MSP58, with the
32P-labeled N19 probe and
competed with unlabeled N19. (F) The same experiment described in (E) was repeated using the N8 RNA as unlabeled competitor.
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complex. To this purpose, we performed GST-pull down
experiments by mixing 4 mM of GST-FMRP with increasing
amounts (1, 2, 4 mM ) of His-FXR1P-Isoe, Isod or Isoa (In
Figure 2D, the results are shown only for interaction bet-
ween FMRP and FXR1P-Isoe). The beads were then treated
with glutathione and the eluted proteins were revealed by
immunoblot using the two monoclonal antibodies 1C3 (24)
and 3FX (21) recognizing FMRP and FXR1P, respectively.
As shown in Figure 2D, the ratio of released FXR1P and
FMRP is around 1:1 when mixed in stochiometric amounts.
This result shows that when the two proteins are mixed
in vitro their association is dose-dependent and, on the other
side, also shows that our results are not due to an unbalanced
ratio of the two interacting proteins in the FXR heterodimers.
Subsequently, we tested the ability of the FXR1P-Isoe/
FMRP heterodimer to bind G-quartet RNA. Indeed, the
FXR1P-Isoe/FMRP complex binds G-quartet RNA with a
comparable afﬁnity as the FMRP homodimer at different
concentrations of competitor RNA (Figure 2E). Surprisingly,
FXR1P-Isod and Isoa inhibit FMRP binding to G-quartet
RNA when these form a heterodimer with the latter
protein (Figure 2E). As a control, MSP58 protein, that
binds G-quartet RNA in a speciﬁc manner (19), was used
(Figure 2E), and its binding to FMRP leads to the same
results as when FMRP is complexed to FXR1P-Isoe. When
we used the N8 probe as a negative control, no displacement
of the equilibrium was observed, as shown in Figure 2F.
In view of these results, we decided to better dissect the
dynamics of FXR1P/G-quartet RNA and FXR1P/FMRP/
G-quartet RNA interactions. We evaluated the velocity of
interaction of the two FXR proteins with G-quartet RNA. For
this purpose 1 pmol of each protein was mixed with 5 fmol of
labeled N19 RNA. At different time points (10, 30, 60, 120,
240 or 300 min), the assay was stopped and the amount of
radioactivity bound by the proteins evaluated by the ﬁlter
binding assay. The time necessary for FMRP/FXR1P-Isoe
heterodimer to bind the half amount of total bound RNA
ligand was estimated to be 9.93 min, which is lower
than the time employed by FMRP or FXR1P homodimers
(33.65 and 19.04 min, respectively) to bind the same amount
of RNA probe (Figure 3A and B ). This result indicates that
the Kon for the heterodimer is higher than the Kon for both
homodimers. Conversely, the presence of MSP58 complexed
with FMRP did not inﬂuence its binding to G-quartet RNA.
We then investigated the kinetics of FXR1P-Isoe and
FMRP dissociation from the G-quartet RNA structure,
when both bind to it as homodimers or as heterodimers.
FMRP was mixed with
32P-labeled N19 RNA and the com-
plex was allowed to form for 10 min on ice. Then 1 mMo f
cold RNA [N19 or N8, as a negative control (25)] was
added, the reaction was stopped after 10, 30, 60, 120, 240
or 300 min and the amounts of retained radioactivity evalu-
ated by ﬁlter binding assay. In this experiment, it is interest-
ing to observe (Figure 4A) that the FXR1P-Isoe homodimer
releases 50% of total bound RNA after only 15 min. As
expected from its higher afﬁnity, the FMRP homodimer
releases the same amount of bound RNA after a longer lapse
of time, around 45 min. The negative controls are shown in
Figure 4B. In this case the binding of recombinant proteins
to G-quartet containing RNA was competed using the N8
probe. Indeed, only 20–25% of the binding is competed
after more than 4 h of incubation.
Finally, the heterodimer FXR1P-Isoe/FMRP and the
complex MSP58/FMRP were analyzed. The effect of the
heterodimer was dramatic: 50% of the labeled RNA was
released after 5 min and 65% of labeled RNA was released
after 10 min (Figure 4C), while the interaction with MSP58
does not change signiﬁcantly the dynamics of the interaction
between the G-quartet RNA and FMRP. In Figure 4D the
negative controls are shown, conﬁrming the speciﬁcity of
the action described in Figure 4C. This data shows that
formation of the FXR1P-Isoe/FMRP heterodimer increases
the dynamics of protein–RNA interaction, favoring the
release of bound mRNA.
DISCUSSION
FMRP is a component of multimolecular complexes involved
in different steps of mRNA metabolism (2,12). A growing list
Figure 3. Association rate of FMRP, Isoe and MSP58. (A) Each protein was mixed with
32P-labeled N19 RNA probe for a time lapse of 10, 30, 60, 120, 180, 240
and 300 min and then each reaction was filtered and the amount of retained radioactivity evaluated. (B) The same experiment described in (A) was repeated
with the complex FMRP/MSP58 and FMRP/Isoe as indicated in the figure.
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of them being RNA binding proteins (19,33). In addition,
several hundreds of mRNAs have been described as putative
targets of FMRP (12,26), however the functional signiﬁcance
of most of the multiple interactions established by FMRP is
still elusive (12,34). A widely accepted hypothesis proposes
that FMRP can transport mRNA in mRNPs shuttling between
structures where RNA translation is repressed and polyribo-
somes (2). In the absence of FMRP, the equilibrium in mRNP
normally containing FMRP is perturbed, resulting in the
deregulation of the expression and localization of a subset
of its target mRNAs (12,26). Based on these considerations,
we reasoned that RNA binding proteins belonging to the
same mRNP complex, FMRP and its interacting proteins
may enter in contact with the same mRNAs and decided to
test the ability of FXR1P to bind the same mRNA targets
and to inﬂuence its afﬁnity for them. Up to date, the functions
of FXR1P (or FXR2P) were inferred to be, by homology and
analogy, similar to that of FMRP (1). Here we propose that
it is not the case, at least for FXR1P.
First, we tested FXR1P afﬁnity for G-quartet forming RNA
structures. It is surprising that among the three isoforms
analyzed only one, the Isoe is able to bind a G-quartet
RNA forming structure, present in a large amount of putative
target RNAs of FMRP (26). The three FXR1P isoforms share
the same RGG box domain. However, it has been reported
that, even though a peptide corresponding to the RGG box
of FMRP binds speciﬁcally G-quartet forming RNA (30),
the corresponding peptide of the RGG box of FXR1P does
not (35), strongly suggesting that the RGG box of FXR1P
is not sufﬁcient per se to bind the G-quartet structure. The
only difference between the two isoforms Isoe and Isod are
two short sequences of 28 (exon 12) and 27 amino acid
(exon 15) (cf. Figure 1A). Only this latter amino acids stretch
appears to have putative RNA binding properties and is
encountered solely in the Isoe isoform able to bind speciﬁc-
ally the G-quartet structure. This 27 amino acid stretch
encoded by FXR1P exon 15 being in close proximity to the
RGG box of FXR1P encoded by sequences of exon 14
(Figure 1A), it may contribute to the binding to G-quartet
mRNA structures together with the RGG box. Alternatively,
the presence of this additional sequence in the FXR1P-Isoe,
as compared to the other shorter isoforms, may alter the struc-
ture of the C-terminal portion of FXR1P, thereby allowing
the binding. In a similar way, a different afﬁnity for RNA
was also shown for different FMRP isoforms. Indeed,
ISO18, a minor isoform of FMRP lacking a small portion
of exon 17 (29), is still able to bind G-quartet RNA (36),
Figure 4. Dissociation rate of FMRP, Isoe, MSP58 and the two complexes FMRP/Isoe and FMRP/MSP58. (A) Each protein was mixed with
32P-labeled N19
RNA probe for 10 min on ice and then an equal amount of unlabeled N19 RNA was added as competitor to each reaction, which was then filtered after a
precise time lapse of 10, 30, 60, 120, 180, 240 and 300 min. The radioactivity retained on the filter was evaluated. (B) The same experiment described in (A)
was repeated using unlabeled N8 RNA as competitor. (C) The same experiment described in (A) was performed using the protein complexes FMRP/Isoe and
FMRP/MSP58. (D) The same experiment described in (C) was performed using the cold N8 RNA as competitor.
304 Nucleic Acids Research, 2007, Vol. 35, No. 1like ISO1 and ISO7 (13,30). In addition, ISO 18 is able to
bind the 30-UTR of FMR1 mRNA (36), that, conversely, is
not bound by ISO1 and ISO7 (13,30).
In adult muscle, where both FMRP and FXR2P are absent,
the FXR1P isoforms encountered both contain exon 15
sequences and correspond to a doublet of 82 (Isog) and
84 kDa (Isoe) (20,21,37). Their ability to bind G-quartet
RNA structure suggests that, in this tissue, speciﬁc RNAs
might be recognized by FXR1P via the interaction with
G-quartet forming structure. Since FXR1P absence has a
strong impact during muscle development (8,9), its RNA
binding capacities are critical per se, independently from
FMRP’s fonction. Indeed, a recent knock-down analysis
for xFxr1 produced a list of putative FXR1P target RNAs.
Interestingly, several of their human homologues harbor a
putative G-quartet structure [(9), and our unpublished data].
In addition, very little is known concerning the precise
function of FXR1P in muscle, and it is possible that muscle-
speciﬁc FXR1P interacting proteins might modulate its
afﬁnity for RNA.
Our analysis to dissect the binding capacities to G-quartet
RNA FXR1P and its heterodimer with FMRP yielded
unexpected ﬁndings. We observed a dramatic effect of the
FMRP/FXR1P heterodimer on the dynamics of complex
formation with G-quartet RNA. This effect was not observed
when FMRP and its other partner MSP58 were mixed
together, suggesting that MSP58 can probably compete for
the same binding site as FMRP. In addition, the interaction
of FMRP with FXR1P-Isoa or Isod strongly reduced FMRP
speciﬁcity for G-quartet RNA. These different behaviors of
the two FMRP-interacting proteins illustrate the complexity
of the functions and interactions that take place in FMRP-
containing mRNPs and in different tissues. FXR1P-Isod and
Isoa are the FXR1P isoforms with the highest expression
in brain, suggesting that in neurons FMRP interacts mostly
with these two isoforms that might regulate negatively its
action. Since in brain and cerebellum FXR1P-Isoe mRNA
is expressed at a low level as revealed by RT–PCR (our
unpublished data), probably only a very small portion of
FMRP may be regulated by FXR1P-Isoe. Conversely,
FMRP and FXR1P-Isoe and Isog isoforms are co-expressed
in myoblasts and in myotubes, suggesting a particular regula-
tion of G-quartet containing target mRNAs during muscle
differentiation but not in adult muscle, where FMRP is not
expressed anymore (21). The present study highlights the
functional differences between FXR1P isoforms and there-
fore emphasizes the importance of the extensive tissue-
speciﬁc alternative splicing undergone by FXR1 mRNA. In
view of these results, it is clear that in each mRNP the
ratio between FMRP and FXR1P different isoforms becomes
important to precisely regulate FMRP function. The modula-
tion of the afﬁnity and/or of the dynamics observed for the
FXR1P/FMRP heterodimer may reﬂect a regulation of the
exchange of mRNAs between mRNPs or trafﬁcking granules
and polyribosomes.
The interaction domain of the two FXR proteins is local-
ized in the N-terminal region of both proteins. This domain
mediates the interaction between FMRP and several other
proteins (FXR2P, CYFIP1, CYFIP2, NUFIP and 82-FIP)
(10,33). On the other hand, despite the high level of homo-
logy, the N-terminal region of FXR1P seems to interact
only with CYFIP2 and FXR2P (18). CYFIP2, together with
CYFIP1, that only interacts with FMRP, belongs to a small
family of proteins linking FMRP to the Rac pathway
(18,33,38). We have previously proposed that the CYFIP pro-
teins might modulate the ability of the FXR family members
to homo and/or heterodimerize (18).
FXR1P and FXR2P are believed to have distincts but
overlapping function in conjunction with FMRP, with the
possibility to partially compensate for its absence. Our results
show here a completely different function for two different
FXR1P isoforms, which modulate the action of FMRP. This
data reveals how a full understanding of FMRP function may
be achieved through the deciphering of the global action of
FMRP-containing mRNP complexes.
ACKNOWLEDGEMENTS
The authors are grateful to Alexandra Charlesworth for help.
B.B. is supported by CNRS, Fondation J. Lejeune, GIS
Maladies Rares, Fondation pour la Recherche Me ´dicale,
FRAXA Foundation and ‘Contrat d’interface’ from INSERM
and CHU de Nice. E.B. is recipient of a fellowship from
Fondation pour la Recherche Me ´dicale. E.L. is supported by
CNRS, Fondation pour la Recherche Me ´dicale and ARC.
L.D. is supported by the FRAXA Foundation and by a short
term fellowship from the Boeringher Ingelheim Fund and the
Conquer Fragile X Foundation. E.W.K. is supported by the
NSERC. The authors also thank the support of the French
Embassy in Canada for their Travelling Exchange Programm.
Funding to pay the Open Access publication charges for this
article was provided by CNRS.
Conflict of interest statement. None declared.
REFERENCES
1. Bardoni,B., Mandel,J.L. and Fisch,G.S. (2000) FMR1 gene and fragile
X syndrome. Am. J. Med. Genet., 97, 153–163.
2. Bardoni,B., Davidovic,L., Bensaid,M. and Khandjian,E.W. (2006)
The fragile X syndrome: exploring its molecular basis and seeking a
treatment. Expert Rev. Mol. Med., 8, 1–16.
3. Siomi,M.C., Siomi,H., Sauer,W.H., Srinivasan,S., Nussbaum,R.L. and
Dreyfuss,G. (1995) FXR1, an autosomal homolog of the fragile X
mental retardation gene. EMBO J., 14, 2401–2408.
4. Zhang,Y., O’Connor,J.P., Siomi,M.C., Srinivasan,S., Dutra,A.,
Nussbaum,R.L. and Dreyfuss,G. (1995) The fragile X mental
retardation syndrome protein interacts with novel homologs FXR1 and
FXR2. EMBO J., 14, 5358–5366.
5. Bakker,C.E., Verheij,C., Willemsen,R., Vanderhelm,R., Oerlemans,F.,
Vermey,M., Bygrave,A., Hoogeveen,A.T., Oostra,B., Reyners,E. et al.
(1994) Fmr1 knockout mice: a model to study fragile X mental
retardation. Cell, 78, 23–33.
6. Morales,J., Hiesinger,P.R., Schroeder,A.J., Kume,K., Verstreken,P.,
Jackson,F.R., Nelson,D.L. and Hassan,B.A. (2002) Drosophila fragile
X protein, DFXR, regulates neuronal morphology and function in the
brain. Neuron, 34, 961–972.
7. Bontekoe,C.J., McIlwain,K.L., Nieuwenhuizen,I.M., Yuva-Paylor,L.A.,
Nellis,A., Willemsen,R., Fang,Z., Kirkpatrick,L.L., Bakker,C.E.,
McAninch,R. et al. (2002) Knockout mouse model for Fxr2: a model of
mental retardation. Hum. Mol. Genet., 11, 487–498.
8. Mientjes,E.J., Willemsen,R., Kirkpatrick,L.L., Nieuwenhuizen,I.M.,
Hoogeveen-Westerveld,M., Verwzeij,M., Reis,S.A., Bardoni,B.,
Hoogeveen,A.T., Oostra,B. et al. (2004) Fxr1 knockout mice show a
striated muscle phenotype: implications for Fxr1p function in vivo.
Hum. Mol. Genet., 13, 1291–1302.
Nucleic Acids Research, 2007, Vol. 35, No. 1 3059. Huot,M.E., Bisson,N., Davidovic,L., Mazroui,R., Labelle,Y., Moss,T.
and Khandjian,E.W. (2005) The RNA-binding protein fragile X-related
1 regulates somite formation in Xenopus laevis. Mol. Biol. Cell, 14,
835–844.
10. Ramos,A., Hollingworth,D., Adinolfi,S., Castets,M., Kelly,G.,
Frenkiel,T.A., Bardoni,B. and Pastore,A. (2006) The structure of the
N-terminal domain of the Fragile X Mental retardation protein: a
platform for protein–protein interaction. Structure, 14, 21–31.
11. Kirkpatrick,L.L., McIlwain,K.L. and Nelson,D.L. (2001) Comparative
genomic sequence analysis of FXR gene family: FMR1, FXR1 and
FXR2. Genomics, 78, 169–177.
12. Khandjian,E.W., Bechara,E., Davidovic,L. and Bardoni,B. (2005)
Fragile X Mental retardation Protein: many partners and multiple
targets for a promiscuous function. Current Genomics, 6, 512–522.
13. Schaeffer,C., Bardoni,B., Mandel,J.L., Ehresmann,B., Ehresmann,C.
and Moine,H. (2001) The fragile X mental retardation protein binds
specifically to its mRNA via a purine quartet motif. EMBO J., 20,
4803–4813.
14. Darnell,J.C., Fraser,C.E., Mostovetsky,O., Stefani,G., Jones,T.A.,
Eddy,S.R. and Darnell,R.B. (2005) Kissing complex RNAs mediate
interaction between the Fragile X mental retardation protein KH2
domain and brain polyribosomes. Genes Dev., 19, 903–918.
15. Chen,L., Yun,S.-W., Seto,J., Liu,W. and Toth,M. (2003) The fragile X
mental retardation protein binds and regulates a novel class of mRNAs
containing U rich target sequenses. Neuroscience, 120, 1005–10017.
16. Garnon,J., Lachance,C., Di Marco,S., Hel,Z., Marion,D., Ruiz,M.C.,
Newkirk,M.M., Khandjian,E.W. and Radzioch,D. (2005) Fragile
X-related Protein FXR1P regulates proinflammatory cytokine tumor
necrosis factor expression at the post-transcriptional level. J. Biol.
Chem., 280, 5750–5763.
17. Khandjian,E.W., Huot,M.E., Tremblay,S., Davidovic,L., Mazroui,R.
and Bardoni,B. (2004) Biochemical evidence for the association of
fragile X mental retardation protein with brain polyribosomal
ribonucleoparticles. Proc. Natl Acad. Sci. USA, 101, 13357–13362.
18. Schenck,A., Bardoni,B., Moro,A., Bagni,C. and Mandel,J.L. (2001)
A highly conserved protein family interacting with the fragile X mental
retardation protein (FMRP) and displayng selective interaction with
FMRP-related proteins FXR1P and FXR2P. Proc. Natl Acad. Sci. USA,
98, 8844–8849.
19. Davidovic,L., Bechara,E., Gravel,M., Jaglin,X.H., Tremblay,S., Sik,A.,
Bardoni,B. and Khandjian,E.W. (2006) The nuclear MicroSpherule
protein 58 is a novel RNA-binding protein that interacts with fragile
mental retardation protein in polyribosomal mRNPs from neurons.
Hum. Mol. Genet., 9, 1–14.
20. Kirkpatrick,L.L., McIlwain,K.L. and Nelson,D.L. (1999) Alternative
splicing in the murine and human FXR1 genes. Genomics, 59,
193–202.
21. Khandjian,E.W., Bardoni,B., Corbin,F., Sittler,A., Giroux,S., Heitz,D.,
Tremblay,S., Pinset,C., Montarras,D., Rousseau,F. et al. (1998) Novel
isoform of the fragile X related protein FXR1P are expressed during
myogenesis. Hum. Mol. Genet., 7, 2121–2128.
22. Bardoni,B., Schenck,A. and Mandel,J.L. (1999) A novel RNA binding
protein that interacts with the fragile X mental retardation (FMR1)
protein. Hum. Mol. Genet., 8, 2557–2566.
23. Mazroui,R., Huot,M.E., Tremblay,S., Boilard,N., Labelle,Y. and
Khandjian,E.W. (2003) Fragile X mental retardation protein
determinants required for its association with polyribosomal
ribonucleoparticles. Hum. Mol. Genet., 12, 3087–3096.
24. Devys,D., Lutz,Y., Rouyer,N., Bellocq,J.P. and Mandel,J.L. (1993)
The FMR-1 protein is cytoplasmic, most abundant in neurons and
appears normal in carriers of a fragile X premutation. Nat. Genet.,
4, 783–789.
25. Castets,M., Schaeffer,C., Bechara,E., Schenck,A., Khandjian,E.W.,
Luche,S., Moine,H., Rabilloud,T., Mandel,J.L. and Bardoni,B. (2005)
FMRP interferes with Rac1 pathway and controls actin cytoskeleton
dynamics in murine fibroblasts. Hum. Mol. Genet., 14, 835–844.
26. Miyashiro,K.Y., Beckel-Mitchener,A., Purk,T.P., Becker,K.G.,
Barret,T., Liu,L., Carbonetto,S., Weiler,I.J., Greenough,W.T. and
Eberwine,J. (2003) RNA cargoes associating with FMRP reveal
deficits in cellular functioning in Fmr1 null mice. Neuron, 37,
417–431.
27. Wang,L. and Brown,S.J. (2006) BinDN: a web-based tool for efficient
prediction of DNA and RNA binding sites in amino acids sequences.
Nucleic Acids Res., 34, W243–W248.
28. Terribilini,M., Lee,J.H., Yan,C., Jernigan,R.L., Honovar,V. and
Dobbs,D. (2006) Prediction of RNA binding sites in proteins from
amino acids sequence. RNA, 12, 1450–1462.
29. Sittler,A., Devys,D., Weber,C. and Mandel,J.L. (1996) Alternative
splicing of exon 14 determines nuclear or cytoplasmic localization of
fmr1 protein isoforms. Hum. Mol. Genet., 5, 95–102.
30. Darnell,J.C., Jensen,K.B., Jin,P., Brown,V., Warren,S.T. and
Darnell,R.B. (2001) Fragile X mental retardation protein targets G
quartet mRNAs important for neuronal function. Cell, 107, 489–499.
31. Gabus,C., Mazroui,R., Tremblay,S., Khandjian,E.W. and Darlix,J.L.
(2004) The fragile X mental retardation protein has nucleic acid
chaperone properties. Nucleic Acids Res., 32, 2623–2631.
32. Wang,H., Iacoangeli,A., Lin,D., Denman,R.B., Hellen,C.U. and
Tiedge,H. (2005) Dendritic BC1 RNA in translational control
mechanisms. J. Cell. Biol., 171, 811–821.
33. Castets,M., Mandel,J.L. and Bardoni,B. (2005) FMRP Interacting
proteins: from a complex to a pathway. In Sung,Y.J. and Denman,R.B.
(eds), The Molecular Basis of Fragile X Syndrome. Research Signpost,
Kerala, India, pp. 117–127.
34. Darnell,J.C., Mostovetsky,O. and Darnell,R.B. (2005) FMRP RNA
targets: identification and validation. Genes Brain Behav., 4, 341–349.
35. Zanotti,J., Lackey,P.E., Evans,G.L. and Milailescu,M.R. (2006)
thermodynamics of the fragile X mental retardation protein RGG
box interaction with quartet forming RNA. Biochemistry, 45,
8319–8330.
36. Rackham,O. and Brown,C.M. (2004) Visualization of RNA–protein
interactions in living cells: FMRP and IMP1 interact on mRNAs.
EMBO J., 23, 3346–3355.
37. Dube,M., Huot,M.E. and Khandjian,E.W. (2000) Muscle specific
fragile X related protein 1 isoforms are sequestred in the nucleus of
undifferentiated myoblast. BMC Genet., 1,4 .
38. Bardoni,B. and Mandel,J.L. (2002) Advances in understanding of
fragile X pathogenesis and FMRP function, and in identification of X
linked mental retardation genes. Curr. Opin. Genet. Dev., 12, 284–293.
306 Nucleic Acids Research, 2007, Vol. 35, No. 1